OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.

Zhenhua XuNajiba MuradDaniel MalawskyRan TaoSamuel Rivero-HinojosaDörthe HoldhofUlrich Schüller Peng Zhang Christopher A Lazarski Brian R RoodRoger PackerTimothy R Gershon Yanxin Pei

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our studies reveal that OLIG2 is a biomarker and an effective therapeutic target in a high-risk subset of MYC-amplified MB, and OLIG2 inhibitor combined with radiotherapy represents a novel effective approach for treating this devastating disease.

Keyphrases

transcription factor
early stage
radiation therapy
genome wide
radiation induced
locally advanced
single cell
gene expression
dna methylation